Contact this trialFirst, we need to learn more about you.
Immunotherapy
NL-201 + Pembrolizumab for Cancer
Recruiting2 awardsPhase 1
Duarte, California
This trial tests the safety and effectiveness of NL-201 alone and with pembrolizumab in patients with advanced cancer. NL-201 may directly affect cancer cells, and pembrolizumab helps the immune system attack cancer. The goal is to find a safe and effective dose and schedule for these treatments. Pembrolizumab has shown efficacy and safety in treating various cancers, including melanoma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service